← Back to All Filings

Director Daniel Allen Gold Receives Annual Equity Award at Roivant Sciences

Low SignificanceSeptember 18, 2026 at 11:37:17 PM UTC

Roivant Sciences Ltd.

$ROIV4CIK: 0001635088

Subscribe to track ROIV

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

šŸ“‹ Form 4 Filing: Roivant Sciences Ltd. ($ROIV) Insider: Daniel Allen Gold (Director) Date: 2026-09-16 | Filed: 2026-09-18

• Transaction: Grant of 5,054 Common Shares (RSUs) @ $0.00 • Post-Transaction Holdings: 8,965,815 shares (Direct) • Derivative Grant: 10,531 Stock Options (Exercise Price: $39.57, Exp: 2036-09-15) • Significance: Low (Routine annual director compensation)

Comprehensive Analysis

Executive Summary

On September 18, 2026, Roivant Sciences Ltd. ($ROIV) director Daniel Allen Gold filed a Form 4 disclosing the receipt of annual equity compensation on September 16, 2026. The transaction consisted of a grant of 5,054 restricted stock units (RSUs) and 10,531 stock options pursuant to the company's Non-Employee Director Compensation Policy.

Transaction Details

  • Security: Common Shares (RSUs)
  • Shares Granted: 5,054
  • Price per Share: $0.00
  • Transaction Code: A (Grant/Award)
  • Vesting Terms: The RSUs vest 100% on September 16, 2027, subject to continued service as a director.
  • Post-Transaction Beneficial Ownership: 8,965,815 common shares held directly.
  • Derivative Grant: 10,531 stock options with an exercise price of $39.57 per share, expiring September 15, 2036, also vesting 100% on September 16, 2027.

Market & Trading Significance

This filing carries Low trading significance as it represents standard annual equity compensation under the company's pre-established Non-Employee Director Compensation Policy. There was no open-market purchase or sale activity.

Topics:#ROIV#RoivantSciences#InsiderTrading#Form4#Biotech

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.